- Golden Biotechnology will be initiating its pivotal global Phase 3 study evaluating Antroquinonol as First-Line treatment for Metastatic Pancreatic Cancer in combination with Nab-Paclitaxel and Gemcitabine. This follows promising Phase 2 results, where Antroquinonol combined with standard therapy demonstrated a significant improvement in Median Overall Survival : 14.1 months vs 8.5 months with standard therapy alone. Offering a clinically meaningful survival advantage. Antroquinonol has also received Orphan Drug Designation from both the FDA and EMA, underscoring its potential impact in this area
- Golden Biotechnology Corp is a leading biopharmaceutical company focused on discovery and clinical development of innovative therapeutic new drugs (NCE) for Oncology and Rare Disease
- It's key compound Antroquinonol have completed numerous Phase 1 and 2 studies in NSCLC, AML and Pancreatic Cancer with promising results.
Address
New Taipei City
Taiwan
)
)
){kind=logo}
){kind=logo}
){kind=logo}